Foresight Diagnostics Announces Three Presentations Highlighting Clinical Studies Using Patented PhasED-Seq® MRD Platform at the 64th American Society of Hematology Annual Meeting and Exposition

/PRNewswire/ -- Foresight Diagnostics, a leader in minimal residual disease (MRD) detection technology, announced today that three studies utilizing their...

Related Keywords

United States ,American ,Jake Chabon ,Davidm Kurtz ,Mark Roschewski ,National Cancer Institute ,American Society Of Hematology Annual Meeting ,Stanford University School Of Medicine ,Ernestn Morial Convention Center ,Program Committee ,Cancer Research ,Lymphoid Malignancies Branch ,Division Of Oncology ,American Society ,Hematology Annual Meeting ,Convention Center ,New Orleans ,Tessa Therapeutics ,Hodgkin Lymphoma ,Potential Surrogate Endpoint ,Pooled Analysis ,Clinical Trial ,Foresight Diagnostic ,Ultrasensitive Circulating Tumor ,Classical Hodgkin Lymphoma ,Stanford University School ,Predicts Outcomes ,Frontline Therapy ,Foresight Diagnostics ,